+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Preterm Birth Prevention and Management Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 110 Pages
  • January 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 5026076

The Preterm Birth Prevention and Management market studied is anticipated to grow with a CAGR of nearly 5.4%, during the forecast period.

- Certain factors that are driving the market growth include Increasing the need for preterm birth prevention and management drugs and Growing focus on targeted therapies and standard of care.

- According to the 2018 report published by the World Health Organization, every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation), and this number is rising. Preterm birth complications are the leading cause of death among children under 5 years of age, responsible for approximately 1 million deaths in 2015.

- Around 75% of these deaths could be prevented with current, cost-effective interventions. Across 184 countries, the rate of preterm birth ranges from 5% to 18% of babies born. Owing to the afore-mentioned factors, the market is expected to observe a steady growth over the forecast period.

Key Market Trends

Progesterone Therapy Holds Significant Share in the Global Preterm Birth Prevention and Management Market

Progesterone is a hormone that helps the uterus grow during pregnancy and keeps it from having contractions. Treatment with progesterone during pregnancy may help some women reduce their risk for premature birth. If one has a short cervix, treatment with vaginal progesterone gel may help prevent premature birth. If one had a spontaneous premature birth in the past and was pregnant with just one baby, 17P shots may help prevent another premature birth. Progesterone shots are a kind of progesterone called 17 alpha-hydroxyprogesterone caproate (also called 17P). The shots may help prevent premature birth.

There are two kinds of progesterone treatment. The first one is Vaginal progesterone which may help reduce the risk for premature birth if one has a short cervix and is pregnant with just one baby. Whereas Progesterone shots may help reduce the risk for premature birth if one has had a premature birth in the past and is pregnant with just one baby.

North America Dominates the Global Preterm Birth Prevention and Management Market

According to the latest report published by the Centers for Disease Control and Prevention (CDC), in 2018, preterm birth affected 1 of every 10 infants born in the United States.

The United States preterm birth rate (births at less than 37 weeks of gestation per 100 total births) rose from 9.57% to 9.85% during 2014-2016.

The increase in the total preterm birth rate largely reflects an increase among late preterm births (34-36 weeks), and among births occurring at 36 weeks. Total and late preterm birth rates rose 4% among births in singleton deliveries. Total and late preterm births also increased among multiple births during 2014-2016.

In 2018, the rate of preterm birth among African-American women (14%) was about 50 percent higher than the rate of preterm birth among white women (9%).

Hence, the rising need for preventing and managing preterm birth is expected to propel the market growth across the region.

Competitive Landscape

The global Preterm Birth Prevention and Management market is competitive and consists of a few major players. Companies like AbbVie Inc., Allergan, AMAG Pharmaceuticals, Bayer AG, Ferring B.V., Merck & Co. Inc., Mylan N.V., Pfizer Inc., Teva Pharmaceutical Industries Ltd., among others, hold the substantial market share in the market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Need for Preterm Birth Prevention and Management Drugs
4.2.2 Growing Focus on Targeted Therapies and Standard of Care
4.3 Market Restraints
4.3.1 Adverse Effects Associated with Medication
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Therapy Type
5.1.1 Progesterone Therapy
5.1.2 Corticosteroid Therapy
5.1.3 Tocolytics Therapy
5.1.4 Antibiotics Therapy
5.1.5 Heparin Profylaxis Therapy
5.1.6 Others
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Parenteral
5.2.3 Vaginal
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Others
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Allergan
6.1.3 AMAG Pharmaceuticals
6.1.4 Bayer AG
6.1.5 Ferring B.V.
6.1.6 Merck & Co. Inc.
6.1.7 Mylan N.V.
6.1.8 Pfizer Inc.
6.1.9 Teva Pharmaceutical Industries Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • Allergan
  • AMAG Pharmaceuticals
  • Bayer AG
  • Ferring B.V.
  • Merck & Co. Inc.
  • Mylan N.V.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.